Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2018, Article ID 2414609, 11 pages
https://doi.org/10.1155/2018/2414609
Review Article

A Comprehensive Review of the Pharmacologic Management of Uterine Leiomyoma

1Program in Adult & Reproductive Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health (NIH), Bethesda, MD, USA
2Department of Obstetrics and Gynecology, Uniformed Services University of the Health Sciences (USUHS), Bethesda, MD, USA
3Department of Obstetrics and Gynecology, Walter Reed National Military Medical Center (WRNMMC), Bethesda, MD, USA

Correspondence should be addressed to William H. Catherino; ude.shusu@onirehtac.mailliw

Received 10 October 2017; Accepted 13 December 2017; Published 28 January 2018

Academic Editor: Wan-Liang Lu

Copyright © 2018 Terrence D. Lewis et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. M. McWilliams and V. M. Chennathukuzhi, “Recent Advances in Uterine Fibroid Etiology,” Seminars in Reproductive Medicine, vol. 35, no. 2, pp. 181–189, 2017. View at Publisher · View at Google Scholar · View at Scopus
  2. S. F. Cramer and A. Patel, “The frequency of uterine leiomyomas,” American Journal of Clinical Pathology, vol. 94, no. 4, pp. 435–438, 1990. View at Publisher · View at Google Scholar · View at Scopus
  3. B. Vollenhoven, “Introduction: The epidemiology of uterine leiomyomas,” Best Practice & Research Clinical Obstetrics & Gynaecology, vol. 12, no. 2, pp. 169–176, 1998. View at Publisher · View at Google Scholar · View at Scopus
  4. L. M. Marshall, D. Spiegelman, R. L. Barbieri et al., “Variation in the incidence of uterine leiomyoma among premenopausal women by age and race,” Obstetrics & Gynecology, vol. 90, no. 6, pp. 967–973, 1997. View at Publisher · View at Google Scholar · View at Scopus
  5. D. D. Baird, D. B. Dunson, M. C. Hill, D. Cousins, and J. M. Schectman, “High cumulative incidence of uterine leiomyoma in black and white women: Ultrasound evidence,” American Journal of Obstetrics & Gynecology, vol. 188, no. 1, pp. 100–107, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. K. H. Kjerulff, P. Langenberg, J. D. Seidman, P. D. Stolley, and G. M. Guzinski, “Uterine leiomyomas: Racial differences in severity, symptoms and age at diagnosis,” Obstetrics, Gynaecology and Reproductive Medicine, vol. 41, no. 7, pp. 483–490, 1996. View at Google Scholar · View at Scopus
  7. G. Pron, M. Cohen, J. Soucie, G. Garvin, L. Vanderburgh, and S. Bell, “The Ontario Uterine Fibroid Embolization Trial. Part 1. Baseline patient characteristics, fibroid burden, and impact on life,” Fertility and Sterility, vol. 79, no. 1, pp. 112–119, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Okolo, “Incidence, aetiology and epidemiology of uterine fibroids,” Best Practice & Research: Clinical Obstetrics & Gynaecology, vol. 22, no. 4, pp. 571–588, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. S. M. Schwartz, L. M. Marshall, and D. D. Baird, “Epidemiologic contributions to understanding the etiology of uterine leiomyomata,” Environmental Health Perspectives, vol. 108, no. 5, pp. 821–827, 2000. View at Publisher · View at Google Scholar · View at Scopus
  10. E. A. Stewart, C. L. Cookson, R. A. Gandolfo, and R. Schulze-Rath, “Epidemiology of uterine fibroids: a systematic review,” BJOG: An International Journal of Obstetrics & Gynaecology, 2017. View at Google Scholar
  11. F. Parazzini, C. La Vecchia, E. Negri, G. Cecchetti, and L. Fedele, “Epidemiologic characteristics of women with uterine fibroids. A case-control study,” Obstetrics & Gynecology, vol. 72, no. 6, pp. 853–857, 1988. View at Publisher · View at Google Scholar · View at Scopus
  12. P. C. Klatsky, N. D. Tran, A. B. Caughey, and V. Y. Fujimoto, “Fibroids and reproductive outcomes: a systematic literature review from conception to delivery,” American Journal of Obstetrics & Gynecology, vol. 198, no. 4, pp. 357–366, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. F. Parazzini, L. Tozzi, and S. Bianchi, “Pregnancy outcome and uterine fibroids,” Best Practice & Research Clinical Obstetrics & Gynaecology, vol. 34, pp. 74–84, 2016. View at Publisher · View at Google Scholar · View at Scopus
  14. L. J. Malone, “Myomectomy: Recurrence after removal of solitary and multiple myomas,” Obstetrics & Gynecology, vol. 34, no. 2, pp. 200–203, 1969. View at Google Scholar · View at Scopus
  15. A. Rossetti, O. Sizzi, L. Soranna, F. Cucinelli, S. Mancuso, and A. Lanzone, “Long-term results of laparoscopic myomectomy: Recurrence rate in comparison with abdominal myomectomy,” Human Reproduction, vol. 16, no. 4, pp. 770–774, 2001. View at Publisher · View at Google Scholar · View at Scopus
  16. J. D. Wright, T. J. Herzog, J. Tsui et al., “Nationwide trends in the performance of inpatient hysterectomy in the United States,” Obstetrics & Gynecology, vol. 122, no. 2, part 1, pp. 233–241, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. J. M. Wu, M. E. Wechter, E. J. Geller, T. V. Nguyen, and A. G. Visco, “Hysterectomy rates in the United States, 2003,” Obstetrics & Gynecology, vol. 110, no. 5, pp. 1091–1095, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. K. J. Carlson, D. H. Nichols, and I. Schiff, “Indications for hysterectomy,” The New England Journal of Medicine, vol. 328, no. 12, pp. 856–860, 1993. View at Publisher · View at Google Scholar · View at Scopus
  19. E. R. Cardozo, A. D. Clark, N. K. Banks, M. B. Henne, B. J. Stegmann, and J. H. Segars, “The estimated annual cost of uterine leiomyomata in the United States,” American Journal of Obstetrics & Gynecology, vol. 206, no. 3, pp. 211–e9, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. A. M. Soliman, H. Yang, E. X. Du, S. S. Kelkar, and C. Winkel, “The direct and indirect costs of uterine fibroid tumors: A systematic review of the literature between 2000 and 2013,” American Journal of Obstetrics & Gynecology, vol. 213, no. 2, pp. 141–160, 2015. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Patel, M. Malik, J. Britten, J. Cox, and W. H. Catherino, “Alternative therapies in management of leiomyomas,” Fertility and Sterility, vol. 102, no. 3, pp. 649–655, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. C. M. Farquhar and C. A. Steiner, “Hysterectomy Rates in the United States 1990–1997,” Obstetrics & Gynecology, vol. 99, no. 2, pp. 229–234, 2002. View at Publisher · View at Google Scholar
  23. R. M. Merrill, “Hysterectomy surveillance in the United States, 1997 through 2005,” Medical Science Monitoring, vol. 14, no. 1, Article ID CR24-31, 2008. View at Google Scholar
  24. Committee on Practice B-G, “Practice bulletin no. 136: management of abnormal uterine bleeding associated with ovulatory dysfunction,” Obstetrics & Gynecology, vol. 122, no. 1, pp. 176–185, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. K. G. Cooper, S. A. Jack, D. E. Parkin, and A. M. Grant, “Five-year follow up of women randomised to medical management or transcervical resection of the endometrium for heavy menstrual loss: Clinical and quality of life outcomes,” British Journal of Obstetrics and Gynaecology, vol. 108, no. 12, pp. 1222–1228, 2001. View at Publisher · View at Google Scholar · View at Scopus
  26. A. E. Lethaby, I. Cooke, and M. Rees, “Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding,” Cochrane Database of Systematic Reviews (Online), vol. 4, Article ID CD002126, 2005. View at Google Scholar · View at Scopus
  27. J. Marjoribanks, A. Lethaby, and C. Farquhar, “Surgery versus medical therapy for heavy menstrual bleeding,” Cochrane Database of Systematic Reviews (Online), vol. 2, p. CD003855, 2006. View at Google Scholar · View at Scopus
  28. A. Lethaby, K. Duckitt, and C. Farquhar, “Non-steroidal anti-inflammatory drugs for heavy menstrual bleeding,” Cochrane Database of Systematic Reviews (Online), vol. 1, p. CD000400, 2013. View at Google Scholar · View at Scopus
  29. O. Ylikorkala and F. R. Pekonen, “Naproxen reduces idiopathic but not fibromyoma-induced menorrhagia,” Obstetrics & Gynecology, vol. 68, no. 1, pp. 10–12, 1986. View at Google Scholar · View at Scopus
  30. A. S. Lukes, P. A. Kouides, and K. A. Moore, “Tranexamic acid: A novel oral formulation for the treatment of heavy menstrual bleeding,” Women's Health Journal (WHJ), vol. 7, no. 2, pp. 151–158, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. K. Wellington and A. J. Wagstaff, “Tranexamic acid: A review of its use in the management of menorrhagia,” Drugs, vol. 63, no. 13, pp. 1417–1433, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. J. Marjoribanks, A. Lethaby, and C. Farquhar, “Surgery versus medical therapy for heavy menstrual bleeding,” Cochrane Database System Reviews, vol. 1, Article ID CD003855, 2016. View at Google Scholar · View at Scopus
  33. American College of Obstetricians and Gynecologists, “ACOG practice bulletin,” Alternatives to Hysterectomy in The Management of Leiomyomas. Obstet Gynecol, vol. 112, no. 2, Part 1, pp. 387–400, 2008. View at Publisher · View at Google Scholar
  34. J. Qin, T. Yang, F. Kong, and Q. Zhou, “Oral contraceptive use and uterine leiomyoma risk: A meta-analysis based on cohort and case-control studies,” Archives of Gynecology and Obstetrics, vol. 288, no. 1, pp. 139–148, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Harrison-Woolrych and R. Robinson, “Fibroid growth in response to high-dose progestogen,” Fertility and Sterility, vol. 64, no. 1, pp. 191-192, 1995. View at Google Scholar · View at Scopus
  36. A. J. Friedman, M. Daly, M. Juneau-Norcross, C. Fine, and M. S. Rein, “Recurrence of myomas after myomectomy in women pretreated with leuprolide acetate depot or placebo,” Fertility and Sterility, vol. 58, no. 1, pp. 205–208, 1992. View at Publisher · View at Google Scholar · View at Scopus
  37. E. E. Wallach and N. F. Vlahos, “Uterine myomas: an overview of development, clinical features, and management,” Obstetrics & Gynecology, vol. 104, no. 2, pp. 393–406, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Venkatachalam, J. S. Bagratee, and J. Moodley, “Medical management of uterine fibroids with medroxyprogesterone acetate (Depo Provera): a pilot study,” Journal of Obstetrics & Gynaecology, vol. 24, no. 7, pp. 798–800, 2004. View at Publisher · View at Google Scholar · View at Scopus
  39. F. Mercorio, R. De Simone, A. Di Spiezio Sardo et al., “The effect of a levonorgestrel-releasing intrauterine device in the treatment of myoma-related menorrhagia,” Contraception, vol. 67, no. 4, pp. 277–280, 2003. View at Publisher · View at Google Scholar · View at Scopus
  40. S. E. Bulun, K. Economos, D. Miller, and E. R. Simpson, “CYP19 (aromatase cytochrome P450) gene expression in human malignant endometrial tumors,” The Journal of Clinical Endocrinology & Metabolism, vol. 79, no. 6, pp. 1831–1834, 1994. View at Publisher · View at Google Scholar · View at Scopus
  41. T. J. Iveson, I. E. Smith, J. Ahern, D. A. Smithers, P. F. Trunet, and M. Dowsett, “Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in healthy postmenopausal women,” The Journal of Clinical Endocrinology & Metabolism, vol. 77, no. 2, pp. 324–331, 1993. View at Publisher · View at Google Scholar · View at Scopus
  42. M. E. Parsanezhad, M. Azmoon, S. Alborzi et al., “A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status,” Fertility and Sterility, vol. 93, no. 1, pp. 192–198, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. G. Attilakos and R. Fox, “Regression of tamoxifen-stimulated massive uterine fibroid after conversion to anastrozole,” Journal of Obstetrics & Gynaecology, vol. 25, no. 6, pp. 609-610, 2005. View at Publisher · View at Google Scholar · View at Scopus
  44. F. K. Varelas, A. N. Papanicolaou, N. Vavatsi-Christaki, G. A. Makedos, and G. D. Vlassis, “The effect of anastrazole on symptomatic uterine leiomyomata,” Obstetrics & Gynecology, vol. 110, no. 3, pp. 643–649, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. M. Shozu, K. Murakami, T. Segawa, T. Kasai, and M. Inoue, “Successful treatment of a symptomatic uterine leiomyoma in a perimenopausal woman with a nonsteroidal aromatase inhibitor,” Fertility and Sterility, vol. 79, no. 3, pp. 628–631, 2003. View at Publisher · View at Google Scholar · View at Scopus
  46. S. G. Hilário, N. Bozzini, R. Borsari, and E. C. Baracat, “Action of aromatase inhibitor for treatment of uterine leiomyoma in perimenopausal patients,” Fertility and Sterility, vol. 91, no. 1, pp. 240–243, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. H. Song, D. Lu, K. Navaratnam, and G. Shi, “Aromatase inhibitors for uterine fibroids,” Cochrane Database of Systematic Reviews, vol. 10, Article ID CD009505, 2013. View at Google Scholar · View at Scopus
  48. N. Wigdorowicz-Makowerowa, H. Panek, H. Marek, T. Maslanka, K. Plonka, and A. Palacha, “Mastication organ functional disorders in elementary school children in city of Wroclaw,” Protet Stomatol, vol. 28, no. 1, pp. 21–25, 1978. View at Google Scholar
  49. Bulletins-Gynecology ACoP, “ACOG practice bulletin,” Surgical Alternatives to Hysterectomy in The Management of Leiomyomas. Number 16, May 2000 (Replaces Educational Bulletin Number 192, May 1994), vol. 73, no. 3, pp. 285–293, 2001. View at Google Scholar
  50. E. S. Surrey and M. D. Hornstein, “Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up,” Obstetrics & Gynecology, vol. 99, no. 5, pp. 709–719, 2002. View at Publisher · View at Google Scholar · View at Scopus
  51. A. J. Friedman, D. I. Hoffman, F. Comite, R. W. Browneller, and J. D. Miller, “Treatment of leiomyomata uteri with leuprolide acetate depot: A double-blind, placebo-controlled, multicenter study,” The Leuprolide Study Group. Obstet Gynecol, vol. 77, no. 5, pp. 720–725, 1991. View at Google Scholar · View at Scopus
  52. D. L. Olive, S. R. Lindheim, and E. A. Pritts, “Non-surgical management of leiomyoma: Impact on fertility,” Current Opinion in Obstetrics and Gynecology, vol. 16, no. 3, pp. 239–243, 2004. View at Publisher · View at Google Scholar · View at Scopus
  53. A. J. Friedman, D. Harrison-Atlas, R. L. Barbieri, B. Benacerraf, R. Gleason, and I. Schiff, “A randomized, placebo-controlled, double-blind study evaluating the efficacy of leuprolide acetate depot in the treatment of uterine leiomyomata,” Fertility and Sterility, vol. 51, no. 2, pp. 251–256, 1989. View at Publisher · View at Google Scholar · View at Scopus
  54. W. D. Schlaff, E. A. Zerhouni, J. A. M. Huth, J. Chen, M. D. Damewood, and J. A. Rock, “Placebo-controlled trial of a depot gonadotropin-releasing hormone analogue (leuprolide) in the treatment of uterine leiomyomata,” Obstetrics & Gynecology, vol. 74, no. 6, pp. 856–862, 1989. View at Google Scholar · View at Scopus
  55. A. J. Friedman, M. S. Rein, D. Harrison-Atlas, J. M. Garfield, and P. M. Doubilet, “A randomized, placebo-controlled, double-blind study evaluating leuprolide acetate depot treatment before myomectomy,” Fertility and Sterility, vol. 52, no. 5, pp. 728–733, 1989. View at Publisher · View at Google Scholar · View at Scopus
  56. J. N. Gutmann and S. L. Corson, “GnRH agonist therapy before myomectomy or hysterectomy,” Journal of Minimally Invasive Gynecology, vol. 12, no. 6, pp. 529–537, 2005. View at Publisher · View at Google Scholar · View at Scopus
  57. M. Malik, J. Britten, J. Cox, A. Patel, and W. H. Catherino, “Gonadotropin-releasing hormone analogues inhibit leiomyoma extracellular matrix despite presence of gonadal hormones,” Fertility and Sterility, vol. 105, no. 1, pp. 214–224, 2016. View at Publisher · View at Google Scholar · View at Scopus
  58. D. Gonzalez-Barcena, R. B. Alvarez, E. P. Ochoa et al., “Treatment of uterine leiomyomas with luteinizing hormone-releasing hormone antagonist Cetrorelix,” Human Reproduction, vol. 12, no. 9, pp. 2028–2035, 1997. View at Publisher · View at Google Scholar · View at Scopus
  59. R. E. Felberbaum, U. Germer, M. Ludwig et al., “Treatment of uterine fibroids with a slow-release formulation of the gonadotrophin releasing hormone antagonist Cetrorelix,” Human Reproduction, vol. 13, no. 6, pp. 1660–1668, 1998. View at Publisher · View at Google Scholar · View at Scopus
  60. R. E. Felberbaum, W. Küpker, M. Krapp, B. Gehl, M. Ludwig, and K. Diedrich, “Preoperative reduction of uterine fibroids in only 16 days by administration of a gonadotrophin-releasing hormone antagonist (Cetrotide),” Reproductive BioMedicine Online, vol. 3, no. 1, pp. 14–18, 2001. View at Publisher · View at Google Scholar · View at Scopus
  61. P. A. Flierman, J. J. L. Oberyé, V. P. M. Van Der Hulst, and S. De Blok, “Rapid reduction of leiomyoma volume during treatment with the GnRH antagonist ganirelix,” BJOG: An International Journal of Obstetrics & Gynaecology, vol. 112, no. 5, pp. 638–642, 2005. View at Publisher · View at Google Scholar · View at Scopus
  62. L. M. Kettel, A. A. Murphy, A. J. Morales, J. Rivier, W. Vale, and S. S. C. Yen, “Rapid regression of uterine leiomyomas in response to daily administration of gonadotropin-releasing hormone antagonist,” Fertility and Sterility, vol. 60, no. 4, pp. 642–646, 1993. View at Publisher · View at Google Scholar · View at Scopus
  63. M. Nisolle, S. Gillerot, F. Casanas-Roux, J. Squifflet, M. Berliere, and J. Donnez, “Immunohistochemical study of the proliferation index, oestrogen receptors and progesterone receptors A and B in leiomyomata and normal myometrium during the menstrual cycle and under gonadotrophin-releasing hormone agonist therapy,” Human Reproduction, vol. 14, no. 11, pp. 2844–2850, 1999. View at Publisher · View at Google Scholar · View at Scopus
  64. K. Englund, A. Blanck, I. Gustavsson et al., “Sex steroid receptors in human myometrium and fibroids: Changes during the menstrual cycle and gonadotropin-releasing hormone treatment,” The Journal of Clinical Endocrinology & Metabolism, vol. 83, no. 11, pp. 4092–4096, 1998. View at Google Scholar · View at Scopus
  65. K. Fiscella, S. H. Eisinger, S. Meldrum, C. Feng, S. G. Fisher, and D. S. Guzick, “Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial,” Obstetrics & Gynecology, vol. 108, no. 6, pp. 1381–1387, 2006. View at Publisher · View at Google Scholar · View at Scopus
  66. S. H. Eisinger, T. Bonfiglio, K. Fiscella, S. Meldrum, and D. S. Guzick, “Twelve-month safety and efficacy of low-dose mifepristone for uterine myomas,” Journal of Minimally Invasive Gynecology, vol. 12, no. 3, pp. 227–233, 2005. View at Publisher · View at Google Scholar · View at Scopus
  67. J. Steinauer, E. A. Pritts, R. Jackson, and A. F. Jacoby, “Systematic review of mifepristone for the treatment of uterine leiomyomata,” Obstetrics & Gynecology, vol. 103, no. 6, pp. 1331–1336, 2004. View at Publisher · View at Google Scholar · View at Scopus
  68. A. A. Murphy, L. M. Kettel, A. J. Morales, V. J. Roberts, and S. S. C. Yen, “Regression of uterine leiomyomata in response to the antiprogesterone RU 486,” The Journal of Clinical Endocrinology & Metabolism, vol. 76, no. 2, pp. 513–517, 1993. View at Publisher · View at Google Scholar · View at Scopus
  69. S. H. Eisinger, S. Meldrum, K. Fiscella, H. D. le Roux, and D. S. Guzick, “Low-dose mifepristone for uterine leiomyomata,” Obstetrics & Gynecology, vol. 101, no. 2, pp. 243–250, 2003. View at Publisher · View at Google Scholar · View at Scopus
  70. R. Sitruk-Ware, “Mifepristone and misoprostol sequential regimen side effects, complications and safety,” Contraception, vol. 74, no. 1, pp. 48–55, 2006. View at Publisher · View at Google Scholar · View at Scopus
  71. R. Sitruk-Ware and I. M. Spitz, “Pharmacological properties of mifepristone: toxicology and safety in animal and human studies,” Contraception, vol. 68, no. 6, pp. 409–420, 2003. View at Publisher · View at Google Scholar · View at Scopus
  72. M. Tristan, L. J. Orozco, A. Steed, A. Ramírez-Morera, and P. Stone, “Mifepristone for uterine fibroids,” Cochrane Database of Systematic Reviews (Online), vol. 8, p. CD007687, 2012. View at Google Scholar · View at Scopus
  73. M. Bagaria, A. Suneja, N. B. Vaid, K. Guleria, and K. Mishra, “Low-dose mifepristone in treatment of uterine leiomyoma: A randomised double-blind placebo-controlled clinical trial,” Australian and New Zealand Journal of Obstetrics and Gynaecology, vol. 49, no. 1, pp. 77–83, 2009. View at Publisher · View at Google Scholar · View at Scopus
  74. M. Engman, S. Granberg, A. R. W. Williams, C. X. Meng, P. G. L. Lalitkumar, and K. Gemzell-Danielsson, “Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial,” Human Reproduction, vol. 24, no. 8, pp. 1870–1879, 2009. View at Publisher · View at Google Scholar · View at Scopus
  75. D. DeManno, W. Elger, R. Garg et al., “Asoprisnil (J867): A selective progesterone receptor modulator for gynecological therapy,” Steroids, vol. 68, no. 10-13, pp. 1019–1032, 2003. View at Publisher · View at Google Scholar · View at Scopus
  76. Q. Xu, N. Ohara, W. Chen et al., “Progesterone receptor modulator CDB-2914 down-regulates vascular endothelial growth factor, adrenomedullin and their receptors and modulates progesterone receptor content in cultured human uterine leiomyoma cells,” Human Reproduction, vol. 21, no. 9, pp. 2408–2416, 2006. View at Publisher · View at Google Scholar · View at Scopus
  77. J. Wang, N. Ohara, Z. Wang et al., “A novel selective progesterone receptor modulator asoprisnil (J867) down-regulates the expression of EGF, IGF-I, TGFβ3 and their receptors in cultured uterine leiomyoma cells,” Human Reproduction, vol. 21, no. 7, pp. 1869–1877, 2006. View at Publisher · View at Google Scholar · View at Scopus
  78. P. Bouchard, N. Chabbert-Buffet, and B. C. J. M. Fauser, “Selective progesterone receptor modulators in reproductive medicine: Pharmacology, clinical efficacy and safety,” Fertility and Sterility, vol. 96, no. 5, pp. 1175–1189, 2011. View at Publisher · View at Google Scholar · View at Scopus
  79. K. Chwalisz, W. Elger, T. Stickler, C. Mattia-Goldberg, and L. Larsen, “The effects of 1-month administration of asoprisnil (J867), a selective progesterone receptor modulator, in healthy premenopausal women,” Human Reproduction, vol. 20, no. 4, pp. 1090–1099, 2005. View at Publisher · View at Google Scholar · View at Scopus
  80. K. Chwalisz, L. Larsen, C. Mattia-Goldberg, A. Edmonds, W. Elger, and C. A. Winkel, “A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata,” Fertility and Sterility, vol. 87, no. 6, pp. 1399–1412, 2007. View at Publisher · View at Google Scholar · View at Scopus
  81. F. M. Horne and D. I. Blithe, “Progesterone receptor modulators and the endometrium: changes and consequences,” Human Reproduction Update, vol. 13, no. 6, pp. 567–580, 2007. View at Publisher · View at Google Scholar · View at Scopus
  82. B. J. Attardi, J. Burgenson, S. A. Hild, and J. R. Reel, “In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone,” The Journal of Steroid Biochemistry and Molecular Biology, vol. 88, no. 3, pp. 277–288, 2004. View at Publisher · View at Google Scholar · View at Scopus
  83. A. R. A. Aiken and J. Trussell, “Recent advances in contraception,” F1000Prime Reports, vol. 6, article no. 113, 2014. View at Publisher · View at Google Scholar · View at Scopus
  84. G. Benagiano, C. Bastianelli, M. Farris, and I. Brosens, “Selective progesterone receptor modulators: An update,” Expert Opinion on Pharmacotherapy, vol. 15, no. 10, pp. 1403–1415, 2014. View at Publisher · View at Google Scholar · View at Scopus
  85. E. D. Levens, C. Potlog-Nahari, A. Y. Armstrong et al., “CDB-2914 for uterine leiomyomata treatment: A randomized controlled trial,” Obstetrics & Gynecology, vol. 111, no. 5, pp. 1129–1136, 2008. View at Publisher · View at Google Scholar · View at Scopus
  86. L. K. Nieman, W. Blocker, T. Nansel et al., “Efficacy and tolerability of CDB-2914 treatment for symptomatic uterine fibroids: A randomized, double-blind, placebo-controlled, phase IIb study,” Fertility and Sterility, vol. 95, no. 2, pp. 767–e2, 2011. View at Publisher · View at Google Scholar · View at Scopus
  87. J. Donnez, T. F. Tatarchuk, P. Bouchard et al., “Ulipristal acetate versus placebo for fibroid treatment before surgery,” The New England Journal of Medicine, vol. 366, no. 5, pp. 409–420, 2012. View at Publisher · View at Google Scholar · View at Scopus
  88. J. Donnez, J. Tomaszewski, F. Vázquez et al., “Ulipristal acetate versus leuprolide acetate for uterine fibroids,” The New England Journal of Medicine, vol. 366, no. 5, pp. 421–432, 2012. View at Publisher · View at Google Scholar · View at Scopus
  89. J. Donnez, F. Vázquez, J. Tomaszewski et al., “Long-term treatment of uterine fibroids with ulipristal acetate,” Fertility and Sterility, vol. 101, no. 6, pp. 1565–e18, 2014. View at Publisher · View at Google Scholar · View at Scopus
  90. P. Stratton, E. D. Levens, B. Hartog et al., “Endometrial effects of a single early luteal dose of the selective progesterone receptor modulator CDB-2914,” Fertility and Sterility, vol. 93, no. 6, pp. 2035–2041, 2010. View at Publisher · View at Google Scholar · View at Scopus
  91. I. De Milliano, D. Van Hattum, J. C. F. Ket, J. A. F. Huirne, and W. J. K. Hehenkamp, “Endometrial changes during ulipristal acetate use: a systematic review,” European Journal of Obstetrics & Gynecology and Reproductive Biology, vol. 214, pp. 56–64, 2017. View at Publisher · View at Google Scholar
  92. J. Donnez and M.-M. Dolmans, “Uterine fibroid management: From the present to the future,” Human Reproduction Update, vol. 22, no. 6, pp. 665–686, 2016. View at Publisher · View at Google Scholar · View at Scopus